A. Kate Sasser

7.6k citations

54 papers · 4.5k indexed · 4 hit papers · h-index 24

Oncology top 1%
Molecular Biology top 5%
Hematology top 0.5%
Immunology top 2%
Genetics top 1%

Co-authors: Brett M. Hall Amy Axel Henk M. Lokhorst Niels W.C.J. van de Donk Tahamtan Ahmadi Nicholas J. Sullivan Tuna Mutis Michael Andreeff
Topics: Multiple Myeloma Research and Treatments (30 papers)Monoclonal and Polyclonal Antibodies Research (18 papers)CAR-T cell therapy research (11 papers)
Cited by: Hematology Oncology Genetics
Journals: Blood PLoS ONE Cancer Research
Partner nations: United States Netherlands Belgium

In The Last Decade

A. Kate Sasser

52 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mesenchymal Stem Cell Transition to Tumor-Associated Fibroblasts Contributes to Fibrovascular Network Expansion and Tumor Progression

2009 653 citations Jennifer L. Dembinski, A. Kate Sasser et al. profile →
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

2016 649 citations Jakub Krejcik, Tineke Casneuf et al. Blood profile →
Interleukin-6 induces an epithelial–mesenchymal transition phenotype in human breast cancer cells

2009 605 citations Nicholas J. Sullivan, A. Kate Sasser et al. Oncogene profile →
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

2016 303 citations Saad Z. Usmani, Brendan M. Weiss et al. Blood profile →

Peers

Countries citing papers authored by A. Kate Sasser

Since Specialization

Citations

This map shows the geographic impact of A. Kate Sasser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Kate Sasser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Kate Sasser more than expected).

Fields of papers citing papers by A. Kate Sasser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Kate Sasser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Kate Sasser. The network helps show where A. Kate Sasser may publish in the future.

Co-authorship network of co-authors of A. Kate Sasser

This figure shows the co-authorship network connecting the top 25 collaborators of A. Kate Sasser. A scholar is included among the top collaborators of A. Kate Sasser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Kate Sasser. A. Kate Sasser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma 2024 ·Carolina Digital Repository (University of North Carolina at Chapel Hill) ·Andrew Belch,Torben Plesner,Paul G. Richardson,Jianping Wang,Huaibao Feng,Brendan M. Weiss,Amy Axel,Imran Khan,Hareth Nahi,(unknown),Ajai Chari,Nizar J. Bahlis,Henk M. Lokhorst,A. Kate Sasser,Saad Z. Usmani,Sagar Lonial,Clarissa Uhlar,Tahamtan Ahmadi	0
2	Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity 2023 ·EBioMedicine ·Ida H. Hiemstra,Kim C. M. Santegoets,Maarten L. Janmaat,Bart E.C.G. de Goeij,(unknown),(unknown),Péter Boross,(unknown),Sieto Bosgra,(unknown),(unknown),Dennis Verzijl,Richard G. Hibbert,Kristine A. Frerichs,Tuna Mutis,Niels W.C.J. van de Donk,Tahamtan Ahmadi,David Satijn,A. Kate Sasser,Esther C.W. Breij	18
3	Mechanistic and pharmacodynamic studies of DuoBody-CD3x5T4 in preclinical tumor models 2022 ·Life Science Alliance ·Kristel Kemper,(unknown),Péter Boross,Mischa Houtkamp,Theo S. Plantinga,(unknown),Saskia M. Burm,Maarten L. Janmaat,Louise A. Koopman,Edward N. van den Brink,(unknown),Dennis Verzijl,Patrick Engelberts,David Satijn,A. Kate Sasser,Esther C.W. Breij	3
4	PRECLINICAL EVALUATION OF EPCORITAMAB COMBINED WITH STANDARD OF CARE AGENTS FOR THE TREATMENT OF B‐CELL LYMPHOMAS 2021 ·Hematological Oncology ·(unknown),Ida H. Hiemstra,(unknown),(unknown),(unknown),Patricia Garrido Castro,(unknown),Roberto S Oliveri,(unknown),(unknown),Edith Szafer‐Glusman,Danita H. Schuurhuis,Julie Blædel,Tahamtan Ahmadi,Esther C.W. Breij,A. Kate Sasser,Maria Jure‐Kunkel	1
5	CNV Radar: an improved method for somatic copy number alteration characterization in oncology 2020 ·BMC Bioinformatics ·David Soong,Jeran K. Stratford,Hervé Avet‐Loiseau,Nizar J. Bahlis,Faith E. Davies,Angela Dispenzieri,A. Kate Sasser,Jordan M. Schecter,Ming Qi,Chad Brown,Wendell Jones,Jonathan J. Keats,Daniel Auclair,Christopher Chiu,Jason Powers,Michael Schäffer	11
6	Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma 2018 ·Experimental Hematology and Oncology ·Saad Z. Usmani,Imran Khan,Christopher Chiu,David Foureau,Lawrence J. Druhan,(unknown),Tineke Casneuf,A. Kate Sasser	12
7	Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab 2017 ·Clinical Cancer Research ·Jakub Krejcik,(unknown),Inger S. Nijhof,Berris van Kessel,Jeroen F. van Velzen,Andries C. Bloem,Marloes E.C. Broekmans,Sonja Zweegman,Johan van Meerloo,René J.P. Musters,Pino J. Poddighe,Richard W.J. Groen,Christopher Chiu,Torben Plesner,Henk M. Lokhorst,A. Kate Sasser,Tuna Mutis,Niels W.C.J. van de Donk	119
8	Proteomic Profiling Reveals Targetable Pathways in MGUS (SLAMF6, TNFRSF8, TIMP1, TRL2) That May Contribute to Disease Progression 2017 ·Blood ·Tineke Casneuf,(unknown),Homer Adams,Andrew C. Lysaght,A. Kate Sasser,Robert A. Kyle,S. Vincent Rajkumar,Shaji Kumar	1
9	Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma 2017 ·Blood Advances ·Tineke Casneuf,Xu Steven Xu,Homer Adams,Amy Axel,Christopher Chiu,Imran Khan,Tahamtan Ahmadi,Xiaoyu Yan,Sagar Lonial,Torben Plesner,Henk M. Lokhorst,Niels W.C.J. van de Donk,Pamela L. Clemens,A. Kate Sasser	160
10	CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma 2016 ·Blood ·Inger S. Nijhof,Tineke Casneuf,(unknown),Berris van Kessel,Amy Axel,Khaja Syed,Richard W.J. Groen,Mark van Duin,Pieter Sonneveld,Monique C. Minnema,Sonja Zweegman,Christopher Chiu,Andries C. Bloem,Tuna Mutis,Henk M. Lokhorst,A. Kate Sasser,Niels W.C.J. van de Donk	275
11	Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Myeloma Based on Prior Lines of Therapy: Updated Analysis of Castor 2016 ·Blood ·María‐Victoria Mateos,Jane Estell,Wolney Barreto,Paolo Corradini,Chang‐Ki Min,Eva Medvedova,Ming Qi,Jordan M. Schecter,Himal Amin,Xiang Qin,William Deraedt,Tineke Casneuf,Christopher Chiu,A. Kate Sasser,Ajay K. Nooka	28
12	Monoclonal antibodies targeting CD38 in hematological malignancies and beyond 2016 ·Immunological Reviews ·Niels W.C.J. van de Donk,Maarten L. Janmaat,Tuna Mutis,Jeroen J. Lammerts van Bueren,Tahamtan Ahmadi,A. Kate Sasser,Henk M. Lokhorst,Paul W.H.I. Parren	237
13	High-Parameter Mass Cytometry (CyTOF) Evaluation of Relapsed/Refractory Multiple Myeloma (MM) Pts (Pts) Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action 2016 ·Blood ·Homer Adams,Frederik Stevenaert,Jakub Krejcik,Koen Van der Borght,Tineke Casneuf,Tina Smets,Jaime Bald,Yann Abraham,Hugo Ceulemans,Greet Vanhoof,Tahamtan Ahmadi,Saad Z. Usmani,Torben Plesner,Sagar Lonial,(unknown),Henk M. Lokhorst,Tuna Mutis,Niels W.C.J. van de Donk,A. Kate Sasser	9
14	Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503) 2015 ·Blood ·Torben Plesner,Hendrik‐Tobias Arkenau,Peter Gimsing,Jakub Krejcik,Charlotte Lemech,Monique C. Minnema,Ulrik Lassen,Jacob P. Laubach,Antonio Palumbo,Steen Lisby,Linda Basse,Jianping Wang,A. Kate Sasser,Mary Guckert,Howard Yeh,Tahamtan Ahmadi,Henk M. Lokhorst,Paul G. Richardson	35
15	Development Of a Serum Biomarker Panel That Predicts Imminent Risk Of Multiple Myeloma (MM) Progression From Premalignancy 2013 ·Blood ·A. Kate Sasser,Tineke Casneuf,Dhammika Amaratunga,(unknown),Shaji Kumar,S. Vincent Rajkumar,Brett M. Hall	3
16	Interleukin-6 induces an epithelial–mesenchymal transition phenotype in human breast cancer cellsbreakdown → 2009 ·Oncogene ·Nicholas J. Sullivan,A. Kate Sasser,Amy Axel,Farhad Vesuna,Venu Raman,Nilsa C. Ramirez,Tatiana M. Oberyszyn,Brett M. Hall	605
17	Fibroblasts Isolated from Common Sites of Breast Cancer Metastasis Enhance Cancer Cell Growth Rates and Invasiveness in an Interleukin-6–Dependent Manner 2008 ·Cancer Research ·Adam Studebaker,Gianluca Storci,Jillian L. Werbeck,Pasquale Sansone,A. Kate Sasser,Simona Tavolari,Tim H.‐M. Huang,Michael W.Y. Chan,Frank C. Marini,Thomas J. Rosol,Massimiliano Bonafè,Brett M. Hall	198
18	Mesenchymal Stem Cells in Cancer: Tumor-Associated Fibroblasts and Cell-Based Delivery Vehicles 2007 ·International Journal of Hematology ·Brett M. Hall,Jennifer L. Dembinski,A. Kate Sasser,Matus Studeny,Michael Andreeff,Frank C. Marini	138
19	Human bone marrow stromal cells enhance breast cancer cell growth rates in a cell line-dependent manner when evaluated in 3D tumor environments 2007 ·Cancer Letters ·A. Kate Sasser,Bethany L. Mundy-Bosse,Kristen M. Smith,Adam Studebaker,Amy Axel,Amanda M. Haidet,Soledad Fernández,Brett M. Hall	102
20	Metabolic Biotinylation Provides a Unique Platform for the Purification and Targeting of Multiple AAV Vector Serotypes 2006 ·Molecular Therapy ·(unknown),A. Kate Sasser,Matthew D. Stachler,Jeffrey S. Bartlett	69

About A. Kate Sasser

A. Kate Sasser is a scholar working on Hematology, Genetics and Oncology, having authored 54 papers that have together received 4.5k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (30 papers), Monoclonal and Polyclonal Antibodies Research (18 papers) and CAR-T cell therapy research (11 papers). The work is most often cited by research in Hematology (1.7k citations), Oncology (2.6k citations) and Genetics (893 citations). A. Kate Sasser has collaborated with scholars based in United States, Netherlands and Belgium. Frequent co-authors include Brett M. Hall, Amy Axel, Henk M. Lokhorst, Niels W.C.J. van de Donk, Tahamtan Ahmadi, Nicholas J. Sullivan, Tuna Mutis, Michael Andreeff, Jennifer L. Dembinski and Frank C. Marini. Their work appears in journals such as Blood, PLoS ONE and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact